Home				Orphan Diseases Drug Development Weekly - Y2007 week 02
DATE	SOURCE	OTHER PARTY INVOLVED	INDICATION(S)	HEADLINES - CLICK TO VIEW FULL RELEASE
01/11/07	Shire (UK)		Hunter syndrome	The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
01/10/07	EMEA - COMP (UK)	ACE Pharmaceuticals (NL)	Malaria	Committee for Orphan Medicinal Products January 2007 Meeting
01/10/07	EMEA - COMP (UK)	Immatics Biotechnologies (DE)	Renal cell carcinoma	Committee for Orphan Medicinal Products January 2007 Meeting
01/10/07	EMEA - COMP (UK)	Santhera Pharmaceuticals (DE)	Leber's hereditary optic neuropathy	Committee for Orphan Medicinal Products January 2007 Meeting
01/10/07	EMEA - COMP (UK)	Pharming Group (NL)	Delayed graft function post organ transplantation	Committee for Orphan Medicinal Products January 2007 Meeting
01/10/07	Viralytics (US)		Melanoma (metastatic)	Ethics Committee Approval to conduct a Phase I study in Breast, Prostate and Melanoma Cancer patients using CAVATAKTM administered intravenously
01/09/07	Anthera Pharmaceuticals (US)		Acute chest syndrome	Anthera Receives IND Approval from FDA to Begin Phase 2 'IMPACTS' Trial With A-001 for Prevention of Acute Chest Syndrome in Patients with Sickle Cell…
01/09/07	Medarex (US)	BioWa (US)	Hodgkin's disease (relapsed or refractory)	BioWa and Medarex Announce Allowance of Investigational New Drug Application for Second-Generation Anti-CD30 Antibody (MDX-1401) Enhanced…
01/08/07	Osiris Therapeutics (US)		Crohn disease	Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn’s Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
01/08/07	Provectus Pharmaceuticals (US)		Melanoma (metastatic)	Provectus Receives Orphan Drug Designation from FDA for Anti-Cancer Agent PV-10 for the Treatment Of Metastatic Melanoma
01/08/07	Xanthus Pharmaceuticals (US)		Acute myeloid leukemia	Xanthus Receives Orphan Drug Designation of Xanafide for the Treatment Of AML